← All trials
NCT03843671
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2019
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Baromedical ServicesLead sponsor
- Dartmouth UniversityCollaborator
- United States Air ForceCollaborator
- Memorial Hermann Health SystemCollaborator
- Mayo ClinicCollaborator
- University of South CarolinaOverall official - principal investigator
- Prisma HealthCollaborator
- Prisma HealthOverall official - principal investigator
- National Baromedical ServicesStudy chair
- Department of Veteran AffairsOverall official - principal investigator
- CISSS de Chaudière-AppalachesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.